BioPharma Resources

Drug Trial Radar · NCT01047540

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection

Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Mar 2010

Primary completion

Dec 2010

Study completion Mar 2011

Sponsor

Sponsor type
Industry
Collaborators
FHI 360
First posted
Jan 13, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes

Conditions

  • HSV-2

Interventions

  • AIC316Drug

    Oral administration

  • AIC316Drug

    Oral administration

  • AIC316Drug

    Oral administration

  • AIC316Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of 4 Different Doses of AIC316 and Matching Placebo With Respect to the Suppression of Herpes Simplex Virus Replication (Shedding Rate)Time frame: 28 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Cetero Research Miami Gardens

    Miami, Florida

  • Indiana University School of Medicine, Office for Research

    Indianapolis, Indiana

  • Westover Heights Clinic

    Portland, Oregon

  • University of Texas Health Science Centre, Center for Clincial Studies

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Washington, Virology Research Clinic

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.